Sellas Life Sciences is trading 5.8% down now at $10.88, with the decline appearing consistent with broader risk-off trading ahead of Tuesday’s Federal Reserve decision.
- The stock fell 14.42% during the September 11 session.
- No fresh company-specific announcement, earnings release, or regulatory catalyst was identified for September 14; the latest company-related items concern previously announced AACR presentations for SLS009.
- Major U.S. futures are lower amid higher oil and technology-sector weakness.